Rofecoxib does not appear to increase the risk of venous thromboembolism: A systematic review of the literature

Our findings are limited by the relatively small number of events, although, the contributing sample size of 28307 subjects (18309 person years) is reasonable. From our best available data outlined in this manuscript, there is no increase in the risk of VTE with rofecoxib use.